Rhumbline Advisers lowered its position in shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 2.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 123,245 shares of the biopharmaceutical company’s stock after selling 3,454 shares during the quarter. Rhumbline Advisers owned about 0.12% of Catalyst Pharmaceuticals worth $629,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its stake in Catalyst Pharmaceuticals by 12.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 308,580 shares of the biopharmaceutical company’s stock valued at $1,166,000 after purchasing an additional 33,767 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Catalyst Pharmaceuticals by 9.6% during the third quarter. JPMorgan Chase & Co. now owns 989,080 shares of the biopharmaceutical company’s stock valued at $3,739,000 after buying an additional 86,692 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 4.3% during the third quarter. Vanguard Group Inc. now owns 4,458,151 shares of the biopharmaceutical company’s stock valued at $16,852,000 after buying an additional 185,017 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 30.8% during the fourth quarter. Alps Advisors Inc. now owns 237,439 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 55,884 shares during the last quarter. Finally, Gables Capital Management Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 7.3% during the fourth quarter. Gables Capital Management Inc. now owns 480,764 shares of the biopharmaceutical company’s stock valued at $923,000 after buying an additional 32,500 shares during the last quarter. Hedge funds and other institutional investors own 59.79% of the company’s stock.
In other Catalyst Pharmaceuticals news, CEO Patrick J. Mcenany bought 25,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was acquired at an average cost of $3.23 per share, for a total transaction of $80,750.00. Following the completion of the transaction, the chief executive officer now owns 4,762,693 shares in the company, valued at $15,383,498.39. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 10.70% of the stock is currently owned by company insiders.
NASDAQ CPRX traded up $0.16 on Wednesday, hitting $4.05. 1,166,472 shares of the stock were exchanged, compared to its average volume of 2,008,282. The company has a quick ratio of 6.07, a current ratio of 6.08 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average price of $3.64. The stock has a market capitalization of $416.56 million, a price-to-earnings ratio of -12.27 and a beta of 2.60. Catalyst Pharmaceuticals Inc has a 52-week low of $1.85 and a 52-week high of $6.16.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.12. The business had revenue of $12.45 million for the quarter, compared to the consensus estimate of $2.40 million. During the same quarter last year, the business posted ($0.06) earnings per share. On average, research analysts forecast that Catalyst Pharmaceuticals Inc will post 0.11 earnings per share for the current year.
Catalyst Pharmaceuticals Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Story: Should you buy a closed-end mutual fund?
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.